458 results on '"Gill, Harinder"'
Search Results
2. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group
3. Eosinophilic Disorders and Systemic Mastocytosis
4. Management of Relapsed or Refractory AML
5. In the Pipeline: Emerging Therapy for CML
6. Prognostic Indicators in MDS and CMML
7. Molecular Landscape and Personalized Prognostic Prediction of MPNs
8. Treatment Algorithm for Primary and Secondary Myelofibrosis
9. In the Pipeline: Emerging Therapy for MDS and MDS/MPN
10. Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: When and How?
11. Modern Classification of Acute and Chronic Leukemias: Integrating Biology, Clinicopathologic Features, and Genomics
12. In the Pipeline—Emerging Therapy for ALL
13. Next-Generation FLT3 Inhibitors for the Treatment of FLT3-Positive AML
14. Management of Relapsed Acute Promyelocytic Leukemia and the Role of Hematopoietic Stem Cell Transplantation
15. Frontline Management of Acute Promyelocytic Leukemia
16. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction
17. Prognostic Models for Primary and Secondary Myelofibrosis
18. Clonal Hematopoiesis and Its Functional Implications in MDS/AML
19. Role of IDH1/IDH2 Inhibitors in AML
20. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
21. Undiagnosed Hypertension in Vancouver’s Punjabi Sikh Community: A Cross-Sectional Study
22. VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).
23. Prioritising the psychosocial needs of young oncology patients: a call for comprehensive care
24. Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
25. CD3+CD4+ lymphoid neoplasm: diagnostic clues for plasmablastic lymphoma instead of peripheral T-cell lymphoma
26. Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients
27. Responsiveness of Output & Prices to Monetary & Fiscal Shocks in India
28. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study
29. Clinical delineation, sex differences, and genotype–phenotype correlation in pathogenic KDM6A variants causing X-linked Kabuki syndrome type 2
30. Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy
31. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations
32. Bomedemstat as an investigative treatment for myeloproliferative neoplasms
33. Idiopathic splenomegaly in childhood and the spectrum of RAS-associated lymphoproliferative disease: a case report
34. MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
35. Rethinking Palliative Care in Psychiatry
36. POSTER: MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
37. MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
38. ORAL arsenic trioxide to combat acute promyelocytic leukaemia
39. RAPIDOMICS: rapid genome-wide sequencing in a neonatal intensive care unit—successes and challenges
40. Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis
41. Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment
42. Editorial: Acute promyelocytic leukemia - towards a chemotherapy-free approach to cure in all patients, Volume II
43. Rheumatology and palliative care: needs and opportunities
44. Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation
45. Complexities in delivering end-of-life care in accordance with patient desires that have been documented
46. Additional file 3 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
47. Additional file 2 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
48. Additional file 4 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
49. Additional file 7 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
50. Additional file 8 of Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.